_{William Todd Penberthy, Ph. D.}

+1 (689) 247-0254 • WTPENBER@GMAIL.COM • WWW.CMESCRIBE.COM

     Winter Park, Florida, USA

 

SUMMARY

 

My scientific experience has been invaluable to my current career, enabling me to gain an understanding of various therapeutic areas and effectively communicate CME grants, biomedical manuscripts, course design, abstracts, slide decks, and more.

 

Therapeutic areas include:

·      Oncology

·      Neurology (multiple sclerosis, other neurodegenerative diseases, epilepsy)

·      Cardiology

·      Rare diseases

·      Nephrology

 

CAREER HISTORY

·      2012 to Current:     Principal writer CMEScribe LLC     

·      Jan 2010-Oct 2012:  Research Professor, University of Central Florida

·      Dec 2004-Dec 2009: Research Professor, University of Cincinnati

·      2000-2004:          Post-doctoral fellow, UCLA

·      1999-2000:          Post-doctoral fellow, Tufts New England Medical Center

 

EDUCATION

 

EXPERIENCE

•       Slide decks, course design, course handouts, KoL identification/interaction

•       Peer-reviewed biomedical manuscripts, reviews, pharmacist guidelines, and meta-analysis:

o   Clinical trial studies

o   Basic science (animal disease models & toxicology)

o   Meta-analysis with statistics

o   Evidence based health technology assessments of emerging technologies

•       Published or submitted: JACC: Cardiovascular Interventions, Nature Immunology, JAMA, BMJ Open, Epilepsia, Journal of Managed Care Specialty Pharmacy, Clinical Nutrition, Antimicrobial Agents and Chemotherapy, Biomaterials, Nanomedicine, Current Pharmaceutical Design, Current Drug Metabolism, J. of Inherited Metabolic Diseases, EPMA J., Nutritional Metabolism, and more

•       Conference abstracts: > 70

•       Systematic review with meta-analysis just published in the Journal of Lasers in Medical Sciences, 2022; Another meta-analysis on topic has been completed. The accepted paper identified 21 RCTs meeting inclusion criteria for involving 1064nm wavelength high-powered (>1.0W) lasers used in photobiomodulation and analysis was performed using Cohen’s d effect size calculations as a means of quantifying efficacy for these devices.

•       Book chapters in dermatology and nutrition: 5

•       Medical technology directory reports: Comprehensive reviews focused on cutting edge medical technologies for practice, budgetary and policy decisions. Subscription only (see https://www.hayesinc.com/hayes/publications/medical-technology-directory/).

•       Scientific Advisor for Aspen Laser Systems, 2021- 2023 published meta-analysis & case study using high-powered 30-watt 810nm laser photobiomodulation to effectively reverse prosopagnosia and eliminate seizures in a patient (published 2022). 

•       White papers focused on high-throughput instrumentation platform assays towards optimal, accurate, and most reliable measures of HbA1c and androstenedione.

•       Textbook chapters:

o  Present Knowledge in Nutrition, Niacin and Biotin, 10^th and 11^th eds.; 2020 & 2012

o  Biochemical, Physiological, and Molecular Aspects of Human Nutrition, Niacin, Riboflavin, and Thiamin, 3^rd and 4^th eds.; 2019 & 2012

•       Invited presentations: Mayo Clinic, Cleveland Clinic, panel participant (PARP1 inhibitors for glioblastoma), etc.

 

SELECT PUBLICATIONS ≤4 YEARS (more upon request)

•       Submissions: JAMA, Epilepsia, Journal of Managed Care Specialty Pharmacy, Clinical Nutrition, Antimicrobial Agents and Chemotherapy, Biomaterials, BMJ Open, and Nanomedicine, (2020-2022)

•       Penberthy, W. Todd and James B. Kirkland. Niacin (2020) in Present Knowledge in Nutrition. 11^th ed., Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.

•       Penberthy, W. Todd, Mahrou Sadri and Janos Zempleni. Biotin (2020) in Present Knowledge in Nutrition. 11^th ed., Elsevier, St. Louis, Mo. Edited by Diane Birt and Allison Worden.

•       Penberthy, W. Todd. Niacin, Riboflavin, and Thiamine (2019) in Biochemical, Physiological, and Molecular Aspects of Human Nutrition. 4^th ed., Elsevier, St. Louis, Mo. Edited by Marie A. Caudill and Martha H. Stipanuk.

•     Penberthy, W. Todd (2009). Nicotinic Acid-Mediated Activation of Both Membrane and Nuclear Receptors Towards Therapeutic Glucocorticoid Mimetics for Potential Treatment of Multiple Sclerosis; PPAR Research 853707-.

•     Penberthy, W. Todd (guest executive editor) Current Pharmaceutical Design, 2009. Developed theme, coordinated authors / reviewers, and provided oversight to completion. Theme: NAD Biology in Disease.

•     Penberthy, W. Todd & Tsunoda, I. (2009). The Importance of NAD in Multiple Sclerosis. Current Pharmaceutical Design. 2009; 15(1): 64-99.

•    Penberthy, W. Todd (2009). Nicotinamide Biology and Disease. Current Pharmaceutical Design;15(1): 1-2.

•.    Jones KS, Alimov AP, Rilo HL, Jandacek RJ, Woollett LA, Penberthy WT. A high throughput live transparent animal bioassay to identify non-toxic small molecules or genes that regulate vertebrate fat metabolism for obesity drug development. Nutr Metab (Lond) 2008;5:23.

•.   Penberthy WT. Pharmacological targeting of IDO-mediated tolerance for treating autoimmune disease. Curr Drug Metab 2007;8:245–66.

 

•    Traver, David, Barry H. Paw, Kenneth D. Poss, W. Todd Penberthy, Shuo Lin, and Leonard I. Zon (2003). Transplantation and in vivo Imaging of Multi-lineage Engraftment in Zebrafish Bloodless Mutants. Nature Immunology. 4:1238-1246. 

 

 

Pubmed publications